Surgical menopause

Surgical menopause

Surgical menopause is sometimes a necessary procedure to reduce the risk of various cancers, but it is associated with some short- and long-term health repercussions. Rahman and Okunoye discuss strategies for deciding the clinical management of patients.

 

Abstract

The word ‘menopause’ derives from the Greek words men (month) and pausis (cessation) and literally means the last menstrual period, also indicating the end of the fertile phase of a woman’s life. The average age for natural menopause is 51 years, the typical age range is 41 to 60 years, and varies depending on ethnicity, family history, co-morbidity and lifestyle.1 In natural menopause, the transition from reproductive years (peri-menopause or climacteric phase) is usually gradual and can take several months to up to a few years. The peri-menopause state is associated with gradual onset of physical symptoms secondary to an overall drop and fluctuations in levels of oestrogen and progesterone, the most common being hot flushes and night sweats.

In the medium term, clinical manifestations include vaginal dryness, reduced libido, urogenital atrophy and psychological effects. Long term consequences include increase in cardiovascular disease, dementia, osteoporosis, sexual dysfunction and body fat redistribution to the abdomen.

In contrast, surgical menopause (bilateral oophorectomy prior to physiological menopause) results in an abrupt reduction in hormone levels with sudden onset of withdrawal symptoms and is associated with increased risk of long term morbidity and mortality.2 Decision for oophorectomy should therefore be made after careful consideration of the individual woman’s demographic, clinical and genetic factors, following thorough counselling of risks and benefits…

 

For the full article, please contact us and ask about subscription:

Jacques Clarkson
T: 0844 858 2890
E: jacques.clarkson@barkerbrooks.co.uk

 

 

References

  1. Gold EB. The timing of the age at which natural menopause occurs. Obstet Gynecol Clin North Am.2011;38:425-440
  2. Rivera CM, Grossardt BR, Rhodes DJ et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause.2009;16:15-23
  3. Moscucci O, Clarke A. Prophylactic oophorectomy: a historical perspective. J Epidemiol Comm Health. 2007; 61:182-184
  4. Chlebowski RT, Anderson GL, Gass M et al. Estrogen plus progestin and breast cancer incidence and mortality in post menopausal women. JAMA.2010; 304:1684-92
  5. Hirasawa A, Masuda K, Akahane T, Tsuruta T, Banno K, Makita K, Susumu N, Jinno H, Kitagawa Y, Sugano K, Kosaki K, Aoki D. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future. Jpn J Clin Oncol. 2013 May;43(5):515-9
  6. Love RR, Philips J. Oophorectomy for breast cancer: history revisited. J Natl Cancer Inst. 2002;94:1433-1434, L
  7. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010;304:967–75.
  8. Pocobelli G, Chubak J, Hanson N, Drescher C, Resta R, Urban N, Buist DS. Prophylactic oophorectomy rates in relation to a guideline update on referral to genetic counselling. Gynecol Oncol. 2012 Aug;126(2):229-35.
  9. Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause. 2006 Mar-Apr;13(2):265-79
  10. Rocca WA, Grossardt BR, Miller VM, Shuster LT, Brown RD Jr. Premature menopause or early menopause and risk of ischemic stroke. Menopause. 2012 Mar;19(3):272-7.
  11. Hickey M, Ambekar M, and Hammond I. Should the ovaries be removed or retained at the time of hysterectomy for benign disease? Human Reproduction Update, Vol.16, No.2 pp. 131–141, 2010
  12. Shuster LT, Gostout BS, Grossardt BR, Rocca WA. Prophylactic oophorectomy in premenopausal women and long-term health. Menopause Int. 2008 Sep;14(3):111-6
  13. Parker WH, Feskanich D, Broder MS, Chang E, Shoupe D, Farquhar CM, Berek JS, Manson JE. Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. Obstet Gynecol. 2013 Apr;121(4):709-16
  14. Sigal BM, Munoz DF, Kurian AW, Plevritis SK. A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1066-77
  15. Greene MH, Mai PL, Schwartz PE. Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers? Am J Obstet Gynecol. 2011 Jan;204(1):19.
  16. http://www.rcog.org.uk/files/rcog-corp/AlternativestoHRTformenopausalsymptoms. RCOG patient information. Published Dec 2011.

 

Categories: ARTICLES

About Author